Q1 2024 Earnings Summary
- DexCom's recent OTC clearance for Stelo significantly expands its addressable market, unlocking a massive opportunity among the 25 million people with type 2 diabetes not on insulin.
- The company is demonstrating significant operating leverage and margin expansion, growing revenue faster than expenses while investing in future growth initiatives, indicating strong financial performance.
- Geographic expansion into key markets like Japan and Europe, alongside new product launches and coverage expansions, provides confidence in achieving guidance and future growth.
- Potential pricing pressures in international markets due to competition and tender systems could impact margins. Kevin Sayer acknowledged offering lower price points for the DexCom 1 product in tender-based European markets to address competition.
- Revenue guidance depends on achieving acceleration through the year, which may be challenging given competitive dynamics and uncertainties in market expansions like Japan and Stelo. Analysts expressed concerns about the company's ability to meet its guidance, noting that new sales representatives take time to become productive and that Stelo's impact may not be significant until later in the year. ,
- Stelo's initial cash-pay model and the anticipated 2-3 years to gain broader payer coverage may limit its near-term impact on revenue. Management indicated that expanding coverage for Stelo is a longer-term objective and does not expect significant coverage expansion in 2024. ,
-
Stelo OTC Launch Impact
Q: How does Stelo OTC clearance expand market and sales?
A: The Stelo OTC clearance opens access to 25 million people with type 2 diabetes not on insulin or without severe hypoglycemia. By eliminating the prescription process, it makes the product very accessible. The sales force is being repositioned to focus more on primary care physicians who see most type 2 patients not on insulin. -
Margin Outlook
Q: How should we think about margin progression this year?
A: We expect 300 to 400 basis points of gross margin expansion over the year. While investments in Japan and the Stelo launch will impact margins, we anticipate some leverage throughout the year, contributing to operating margin expansion despite a slight gross margin decrease compared to prior year. -
Basal Patient Adoption
Q: How is basal scaling; any insights on market share?
A: Basal adoption is progressing as expected, contributing significantly to a record new patient quarter. We aim to increase adoption from 15% to 23% of the basal population in the U.S. this year. We see ourselves taking market share, supported by script data showing growth in this segment. -
Competitor Pricing Pressure
Q: How are you considering potential pricing pressure from competitors?
A: We are comfortable with our pricing and contracts in the U.S., offering features like connection to multiple devices, share follow system, and direct Apple Watch integration. Our pricing is set regardless of AID usage, and we feel confident even in tender systems internationally. -
Sales Force Expansion
Q: Can you elaborate on the sales force expansion and impact?
A: We've repositioned our sales force to focus more on endocrinologists and high prescribers while adding resources to target primary care physicians. The expansion allows us to cover more ground, enhancing our presence in both existing markets and with the Stelo launch. -
15-Day Sensor Plans
Q: What are the steps to bring a 15-day sensor to G7?
A: We are conducting clinical and R&D efforts to move the G7 platform to 15 days, expected after 2024. Economically, this shift reduces sensors sold over 30 days from three to two, improving margins if reliability is maintained. -
Early Treatment Coverage Expansion
Q: Are payers expanding coverage earlier in the treatment paradigm?
A: Some plans cover all people with diabetes, but broader expansion is not expected in 2024. We anticipate that real-world data from Stelo and ongoing clinical work will help demonstrate value to payers over the next 2–3 years. -
Japan Market Launch
Q: What steps are you taking in Japan given coverage there?
A: We are going direct in Japan due to minimal penetration with our previous distributor. Building infrastructure and relationships will take time, but we expect Japan to become a significant market in the future. -
Attrition and Reorder Rates
Q: What's happening with attrition and reorder rates during G7 transition?
A: Retention and utilization rates between G6 and G7 are relatively consistent. We have not seen significant differences across patient populations to date, but we will monitor as we expand into non-intensive insulin therapy segments. -
Resource Allocation for Stelo
Q: How will you allocate resources between Stelo and core products?
A: We have capacity to support Stelo without impacting core products. We will continue to prioritize resource allocation to maximize returns and serve unmet needs efficiently.